Research results determine the future of the company
As part of laboratory studies, PM&HM technologies have been proved to be applicable for the following list of drugs:
No.
Drug
Area of application
Status
1
Hixozide
Tuberculosis
Laboratory tests have been completed. Hexoside and both of its constituent components, Dioxidine and Isoniazid, are compatible with PM&HM technologies.
2
Isoniazid
Tuberculosis
Laboratory tests have been completed. The drug is PM&HM compatible. Marketing authorization condition: change of a packaging.
3
Moxifloxacin
Tuberculosis
Laboratory tests have been completed. The drug is PM&HM compatible.
Marketing authorization condition: pre-clinical/clinical trials required (new dosage form, new route of administration)
4
Levofloxacin
Tuberculosis, pneumonia
Laboratory tests in process. Completion period – September 2020.
5
Amikacin
Tuberculosis, pneumonia
Laboratory tests have been completed. The drug is PM&HM compatible.
Marketing authorization condition: change of a packaging.
6
Tobramycin
Pneumonia, cystic fibrosis
Laboratory tests have been completed. The drug is PM&HM compatible.
Marketing authorization condition: change of a packaging.
7
Gentamicin
Pneumonia
Laboratory tests have been completed. The drug is PM&HM compatible.
Marketing authorization condition: change of a packaging.
8
Budesonide
Asthma, COPD
Laboratory tests have been completed. The drug is PM&HM compatible. The world's first budesonide "solution for inhalation" has been developed, suitable for use in MESH nebulizers.
9
Salbutamol
Asthma, COPD
Laboratory tests have been completed. The drug is PM&HM compatible. Marketing authorization condition: change of a packaging.
10
Tiotropium bromide
Asthma, COPD
Laboratory tests have been completed. The drug is PM&HM compatible.